Etoricoxib, a cyclo-oxygenase-2 inhibitor, appears to be an effective treatment alternative to indomethacin for patients with gouty arthritis, according to findings from a multi-centre trial. The demographics of patients enrolled in the study were typical of those with acute gout. This, together with the diversity of the study sites, means that the results are likely to be applicable to patients with acute gout in general, say Dr. Ralph Schumacher and colleagues at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States.
The double blind, placebo controlled study was carried out at 43 outpatient study centres in 11 countries. Cohorts were made up of 142 men and eight women, or 75 patients per treatment group, aged 18 and older, who presented with clinically diagnosed acute gout within 48 hours of onset. Patients received either etoricoxib 120 mg administered orally once daily for eight days, or indomethacin 50 mg. administered orally three times daily for eight days.
Non-steroidal anti-inflammatory drugs are most often prescribed for the condition, and indomethacin is the standard treatment. The clinicians declare that even though indomethacin is widely used, ‘its efficacy is based on few studies and it is associated with significant side effects in the gastrointestinal tract and central nervous system.’
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!